234 related articles for article (PubMed ID: 26585939)
1. [Nivolumab, a new hope in non-small cell lung cancer].
Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
5. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Lim JS; Soo RA
Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
[TBL] [Abstract][Full Text] [Related]
9. [Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
de Chabot G; Justeau G; Pinquié F; Nadaj-Pakleza A; Hoppé E; Hureaux J; Urban T
Rev Pneumol Clin; 2017 Dec; 73(6):326-330. PubMed ID: 29169677
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
11. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Ulmeanu R; Antohe I; Anisie E; Antoniu S
Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
[TBL] [Abstract][Full Text] [Related]
14. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
15. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
17. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
18. [Pembrolizumab in adjuvant therapy in non-small cell lung cancers].
Lefèvre A; Tissot C
Bull Cancer; 2024 Apr; 111(4):334-336. PubMed ID: 38471995
[No Abstract] [Full Text] [Related]
19. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
20. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
Mahjoubi L; Gazzah A; Marabelle A; Le Roy Ladurie F; Lambotte O; Caramella C; Adam J; Besse B; Soria JC
Eur J Cancer; 2017 Nov; 85():155-157. PubMed ID: 28917814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
